Brief: AIM ImmunoTech Reports Positive Mid-Year Safety And Efficacy Data From Phase 2 Study Evaluating Ampligen® (Rintatolimod) In Combination With AstraZeneca’S Imfinzi® (Durvalumab) For The Treatment Of Pancreatic Cancer
28/07/2025 14:14
July 28 (Reuters) - AIM ImmunoTech Inc AIM.A: AIM IMMUNOTECH REPORTS POSITIVE MID-YEAR SAFETY AND EFFICACY DATA FROM PHASE 2 STUDY EVALUATING AMPLIGEN® (RINTATOLIMOD) IN COMBINATION WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB) FOR THE TREATMENT OF PANCREATIC CANCER AIM IMMUNOTECH INC - NO SIGNIFICANT TOXICITY; 64% OS >6 MONTHS Source text: ID:nGNXDRglG Further company coverage: AIM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential